GENERAL6 Sept 2026
With 300% rally in 5 years, multibagger stock in focus on Monday | Here's why - Details from exchange filing | Stock Market News
Sudarshan Pharma will be in focus Monday after its board approved buying a 9.5% stake in MedTherapy Biotechnology, a Boston-based cancer therapy company. The deal helps Sudarshan enter the US market and gain access to MedTherapy's customers, contracts, and distribution network. The acquisition, expected to complete by March 31, 2027, follows a 369% multibagger rally in three years.
Key Statutory Highlights
- Sudarshan Pharma's board approved buying a 9.50% equity stake in MedTherapy Biotechnology Inc through an exchange filing dated 5 September.
- MedTherapy is a Boston-based cancer cell and gene therapy company, founded in 2018 by experts from Harvard and former Novartis executives.
- Sudarshan Pharma shares have rallied 369.29% in three years and closed at ₹39.42 on Friday, with a market cap of ₹984.16 crore.
Actionable Advice for Taxpayers / Founders:If you are tracking this stock, review the company's exchange filing and monitor regulatory approvals before the deal completes by March 31, 2027.
Statutory Disclaimer: TaxQue Shorts are AI-assisted editorial briefs for compliance awareness. This brief has not passed every source check; confirm the original notification before acting. This does not constitute formal legal or CA counsel.
TaxQue News Desk
Share: